Search
Semaglutide Clinical Trials
A collection of 179 research studies where Semaglutide is the intervention. These studies are located in the United States. Semaglutide is used for conditions such as Diabetes Mellitus, Type 2, Obesity and Diabetes.
85 - 96 of 179
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Study
Recruiting
Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Allergic Asthma
Featured Trial
Studying an Investigational Virus Vaccine
Recruiting
The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.
Conditions:
Healthy
Interested in vaccine studies
All Conditions
Preventative Trials
Semaglutide for Post-Smoking Cessation Weight Management
Recruiting
This trial will examine the effect of semaglutide 2.4mg on changes in body weight, body composition, and peripheral and central mechanisms that control appetite, satiety, and food intake in the context of smoking cessation.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/09/2024
Locations: The University of Texas at Austin, Austin, Texas +1 locations
Conditions: Obesity, Overweight, Cigarette Smoking
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
Completed
The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide in adult participants who have obesity or overweight with weight related comorbidities without Type 2 Diabetes. The study will last around 74 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: Cahaba Research, Birmingham, Alabama +31 locations
Conditions: Obesity, Overweight
Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes
Recruiting
This project uses both transcriptomic- and genomic-level data to identify mechanisms of individual responses to glucagon-like peptide-1 (GLP-1) in Mexican-Americans with prediabetes. The GLP-1 hormone is essential for glucose reduction, weight loss, cardiovascular risk reduction, and renal protection. Newly discovered mechanisms will illuminate causal links between disease genotype and phenotype, which may ultimately guide personalized therapeutic approaches for type 2 diabetes, prediabetes, obe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: UTHealth Clinical Research Unit (CRU) at UT Brownsville, Brownsville, Texas
Conditions: PreDiabetes
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
Active Not Recruiting
The purpose of this study is to learn how well efinopegdutide works compared to placebo in people who have non-alcoholic steatohepatitis (NASH). Researchers will also learn about the safety and benefit of efinopegdutide and how well people tolerate the medicine. The main goal of the study is to compare how many people taking efinopegdutide or placebo stop showing evidence of NASH without liver scarring getting worse.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/28/2024
Locations: The Institute for Liver Health II dba Arizona Clinical Trial-The Institute for Liver Health ( Site 3, Chandler, Arizona +174 locations
Conditions: Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults
Active Not Recruiting
Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, semaglutide has on people who take the drug and the drug's effect on physical function, body composition, and aging.
Gender:
ALL
Ages:
Between 65 years and 90 years
Trial Updated:
11/21/2024
Locations: UT Health San Antonio, San Antonio, Texas
Conditions: Aging, Diabetes Mellitus, Type 2, PreDiabetes, Overweight and Obesity
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss and Fat Loss
Active Not Recruiting
This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®). This study will be done in 3 parts, Part A, Part B, and Part C where different study drugs will be tested.
Part A of the study is focused on healthy participants. Part B and C of the study is focused on participants with obesity.
The aim of Part A of the study is to see how safe and tolerable the study drug is in healthy participants. Th... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/21/2024
Locations: Pinnacle Research Group, Anniston, Alabama +58 locations
Conditions: Obesity
A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)
Completed
The goal of this study is to learn what happens in a person's body over time when they take enlicitide decanoate and semaglutide alone or at the same time. Enlicitide decanoate is a new medicine that lowers the amount of cholesterol in a person's blood. Semaglutide is a drug used to treat type 2 diabetes.
Researchers want to learn what happens to the amount of semaglutide and enlicitide decanoate in a person's blood when each drug is taken alone and when they are taken together.
Gender:
ALL
Ages:
Between 19 years and 55 years
Trial Updated:
11/19/2024
Locations: Celerion (Site 0001), Lincoln, Nebraska
Conditions: Healthy
Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes
Recruiting
This trial plans to learn more about the effects of a medication, semaglutide, on cardiovascular function, kidney function, and insulin sensitivity in adults with type 1 diabetes. This medication has been effective in reducing cardiovascular disease and diabetic kidney disease and improving glucose control and BMI in adults with type 2 diabetes. This study aims to look at how well the medication works in people with type 1 diabetes. Semaglutide is not approved by the FDA to be used in this way.... Read More
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
11/15/2024
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado +1 locations
Conditions: Diabetes Mellitus, Type 1
Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis
Completed
This study will look at participants body weight from the start to the end of the study. It will also look at how much pain participants have in participants knee from the start to the end of the study and how this affects participants daily life. This is to compare the effect on body weight and pain in the knee in people taking semaglutide with people taking "dummy" medicine. Participants will either get semaglutide or "dummy" medicine. Which treatment participants get is decided by chance.
Pa... Read More
Gender:
ALL
Ages:
All
Trial Updated:
11/10/2024
Locations: Baptist Health System, Montgomery, Alabama +65 locations
Conditions: Obesity
Prevention of Progression of Prediabetes, Obesity and CV Risk
Recruiting
The investigators are studying how to help people with prediabetes (Pre-DM) and obesity. The goal is to use new and affordable treatments to bring blood sugar levels back to normal and help participants to lose weight. The investigators also want to reduce participants risk of heart problems. The study team will look at how these treatments affect metabolism and other body functions to help find new ways to treat diabetes and obesity in the future.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/15/2024
Locations: University of Texas Health Science Center at San Antonio, San Antonio, Texas
Conditions: Pre-Diabetes, Weight, Body, Cardiovascular Diseases
A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose
Completed
In this study, a known investigational medicine called 'semaglutide' will be tested in 2 drug concentrations of 0.68 milligram per milliliter (mg/mL) and 1.34 mg/mL. Both drug concentrations are tested for the treatment of type 2 diabetes. The U.S. Food and Drug Administration (FDA), has approved semaglutide in prefilled pen-injector form. Currently, the drug concentration of 1.34 mg/ml can be prescribed in some countries including U.S. The objective of the study is to compare the amount of inve... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
10/13/2024
Locations: Altasciences Clinical LA, Inc., Cypress, California
Conditions: Diabetes Mellitus, Type 2, Healthy Participants
A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight
Completed
This study compares how three doses of semaglutide work in participants with type 2 diabetes (T2D) and overweight who are taking metformin. The study will look mainly at how well participant's blood sugar and participant's body weight are controlled when they are taking the study medicine at different doses. Participants will either get semaglutide \[2 milligrams (mg), 8 mg, or 16 mg\] or semaglutide placebo (a dummy medicine). Participants will take the study medicine with an injection pen call... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
10/10/2024
Locations: Univ of Alabama Birmingham, Birmingham, Alabama +71 locations
Conditions: Diabetes Mellitus, Type 2
85 - 96 of 179